Allopurinol Doesn't Increase All-Cause Mortality, Study Says

the MPR take:

Allopurinol initiators with hyperuricemia and gout have a modestly reduced risk of death, according to a study published in the Annals of the Rheumatic Diseases. The research analyzed a UK general population database for patients ≥40 years of age with a history of hyperuricemia (serum urate level >357μmol/L for women, >416μmol/L for men) from January 2000–May 2010. The group of 5,927 individuals receiving allopurinol had a lower risk of all-cause mortality compared to the matched control group (matched HR 0.89; 95% CI 0.80–0.99). These findings show that despite rare but potentially fatal adverse effects associated with allopurinol, the benefits of the most common treatment for lowering urate could outweigh this risk. 

Allopurinol Doesn't Increase All-Cause Mortality, Study Says
Allopurinol Doesn't Increase All-Cause Mortality, Study Says

Background: Allopurinol is the most commonly used urate-lowering therapy, with rare but potentially fatal adverse effects. The study population included individuals aged 40 years who had a record of hyperuricaemia (serum urate level >357 mol/L for women and >416 mol/L for men) between January ...

READ FULL ARTICLE From ard.bmj.com

Loading links....